ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	3.18T +113.4%
Revenue (ttm)	331.68B +21.2%
Net Income	54.99B +58.4%
EPS	2,688.35 +51.1%
Shares Out	20.84M
PE Ratio	56.73
Forward PE	39.44
Dividend	500.00 (0.31%)
Ex-Dividend Date	Mar 30, 2026

Volume	233,609
Average Volume	149,854
Open	161,700
Previous Close	163,400
Day's Range	150,900 - 162,100
52-Week Range	70,800 - 172,100
Beta	0.35
RSI	52.07
Earnings Date	Apr 27, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2025, ST Pharm's revenue was 331.68 billion, an increase of 21.16% compared to the previous year's 273.75 billion. Earnings were 54.99 billion, an increase of 58.42%.